Related Experiment Video
Updated: Feb 26, 2026
A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
Published on: September 28, 2016
Protective effects of tenuigenin on Staphylococcus aureus-induced pneumonia in mice
Bin Yu1, Jiutao Qiao2, Yongbin Shen3
1Department of Pediatrics, The First Hospital of Harbin Medical University, Harbin, China.
Insights
Tenuigenin (TGN) effectively protected mice against Staphylococcus aureus pneumonia by reducing inflammation and inhibiting key pathways. This study suggests TGN as a potential therapeutic agent for bacterial pneumonia.
Area of Science:
- Pharmacology
- Immunology
- Microbiology
Background:
- Pneumonia is a leading cause of child mortality worldwide.
- Staphylococcus aureus (S. aureus) is a significant bacterial pathogen causing pneumonia.
- Tenuigenin (TGN), derived from Polygala tenuifolia, exhibits known anti-inflammatory properties.
Purpose of the Study:
- To investigate the protective effects of Tenuigenin (TGN) against Staphylococcus aureus-induced pneumonia in a mouse model.
- To elucidate the underlying mechanisms of TGN's action in pneumonia.
Main Methods:
- Induction of pneumonia in mice using Staphylococcus aureus.
- Administration of Tenuigenin (TGN) to assess its therapeutic effects.
- Evaluation of lung histopathology, wet/dry ratio, inflammatory cytokines (TNF-α, IL-1β), and NF-κB activation.
Main Results:
- TGN significantly reduced S. aureus-induced lung histopathological damage.
- TGN treatment decreased lung edema, indicated by a lower wet/dry ratio.
- TGN inhibited the production of pro-inflammatory cytokines TNF-α and IL-1β.
- TGN suppressed S. aureus-induced activation of the NF-κB signaling pathway.
Conclusions:
- Tenuigenin (TGN) demonstrates significant protective effects against Staphylococcus aureus-induced pneumonia in mice.
- The therapeutic action of TGN is mediated through the inhibition of NF-κB activation and subsequent reduction in inflammation.
- TGN shows promise as a potential therapeutic agent for treating S. aureus pneumonia.
Abstract:
Pneumonia is the leading cause of death in infants and young children. Staphylococcus aureus (S.aureus) is one of the most important bacteria that leads to pneumonia. Tenuigenin (TGN), a major active component isolated from the root of the Chinese herb Polygala tenuifolia, has been known to have anti-inflammatory effect. In this study, we aimed to investigate the protective effects of TGN on S.aureus-induced pneumonia in mice. The results showed that TGN significantly attenuated S.aureus-induced lung histopathological changes. TGN also inhibited lung wet/dry (W/D) ratio, and inflammatory cytokines TNF-α and IL-1β production. Furthermore, S.aureus-induced NF-κB activation was significantly inhibited by the treatment of TGN. In conclusion, the results of this study showed that TGN protected against S.aureus-induced pneumonia by inhibiting NF-κB activation. TGN might be a potential agent in the treatment of pneumonia induced by S.aureus.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
09:15A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
Published on: February 28, 2019